Interesting ImagesSimilar Findings on 68Ga-Pentixafor PET/CT and 18F-FDG PET/CT in a Patient With Widespread Metastatic Hepatic Neuroendocrine CarcinomaDeng, Maoxue MD∗,†,‡; Shu, Qiaoqiao MD∗,†,‡; Hu, Mei MD§; Chen, Yue MD∗,†,‡; Cai, Liang PhD∗,†,‡ Author Information From the ∗Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University †Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province ‡Institute of Nuclear Medicine §School of Pharmacy, Southwest Medical University, Luzhou, Sichuan, China. Received for publication July 8, 2022; revision accepted September 13, 2022. Conflicts of interest and sources of funding: none declared. Correspondence to: Liang Cai, PhD, Institute of Nuclear Medicine, Southwest Medical University. No. 25, Taiping St, Luzhou, Sichuan, China 646000. E-mail: [email protected]. Clinical Nuclear Medicine 48(2):p 179-181, February 2023. | DOI: 10.1097/RLU.0000000000004442 Buy Metrics Abstract A patient with suspected malignant tumor underwent 18F-FDG PET/CT. Based on the findings, the patient was suspected of having multiple myeloma. Then the patient underwent 68Ga-pentixafor PET/CT, which showed similar results to 18F-FDG PET/CT. Finally, the patient was eventually diagnosed with neuroendocrine carcinoma. Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.